The Horizon Europe-funded ASCERTAIN project aims to develop new pricing, cost-effectiveness, and reimbursement models that balance incentives for developing new and effective health technologies with sustainable patient access. A key component of the project is the development of an access-based pricing model for medicinal products. This work, led by experts at the Pharmacoeconomics Department at GÖG in collaboration with AIM and Erasmus University Rotterdam, focuses on creating a new pricing model that considers various price determinants such as cost and value elements.
Over the past year, the team has conducted literature reviews on fair pricing definitions, pricing policies, and a wide range of potential price determinants (e.g. R&D and production costs, public contributions, added therapeutic value, and environmental impacts, among others), and consulted stakeholders including healthcare payers, healthcare professionals, patient organizations, researchers, industry experts and investors, through expert interviews and written consultations. The progress made in this work package was presented at two recent ASCERTAIN consortium meetings (one in Madrid and one online), where experts from the Pharmacoeconomics Department shared their ongoing work with the consortium and the international advisory board. Over the coming year, the work conducted so far will be developed into a draft model and we will seek stakeholder input through an online survey.
- Learn more about outputs produced by the Pharmacoeconomics Department: https://ppri.goeg.at/ascertain_project
- Learn more about the ASCERTAIN project: https://www.access2meds.eu/
Foto credits: ASCERTAIN